



EFFICACY OF TOPICAL ATROPINE IN THE PREVENTING DISEASE OF MYOPIC ADVANCEMENT IN YOUNG KIDS

¹Kamran Safdar, ²Dr Khalid Rafique, ³Dr Zulfiqar Uddin Syed, ⁴Dr Tanveer Ahmed, ⁵Khizer Javed, ⁶Hammad Murad

¹UHS Lahore

²Assistant professor of ophthalmology, Rashid Latif Medical College, Lahore.

³Associate Professor of Ophthalmology, MMC General Hospital Peshawar

⁴Assistant Professor Eye CMH Kharian Medical College Kharian Cantt

⁵PIMS Islamabad

⁶UHS Lahore

Vol: 16/03, 511-525

Received: December 21, 2024 Accepted: March 22, 2025 Published: May 16, 2025

ABSTRACT:

Aim: To conduct a literature review on effectiveness of topical atropine in preventing disease of myopic advancement in young kids. **Methods:** Literature searches remained only performed in PubMed database from June 2023 to June 2023, with really not any date limitations, but remained incomplete to researches available in English, and in Cochrane Library record without no constraints. The consolidated searches produced 108 citations, 26 of that remained read in complete. The panel explanatory research design then delegated a strength of proof rating to the 16 articles that were considered fit for incorporation in this evaluation. **Results:** There were nineteen level I, II, and III research recognized. The majority of these studies found that atropine treatment resulted in much less myopic advancement in kids exposed to different healthy controls. All ten level I researches II studies that mainly assessed myopic advancement found that atropine reduced myopic development (ranging from 0.050.64 to 0.480.92 diopters) especially in comparison to control subjects (ranging from 0.370.40 to 1.183.49 diopters). A putback change was found in studies that assessed myopic advancement after treatment discontinuation. Numerous researchers analyzed the optimal atropine dose of medication in terms of myopic progression, putback upon decompensation, and adverse reactions reductions. Lesser atropine dosages (0.6 percent, 0.2 percent, and 0.02 percent) had been found to be moderately less efficient all through 2- to 3-year intervention sessions, but they have been affiliated with far less rebound myopic progression (for atropine 0.02 percent, actually imply myopic advancement upon procedure cessation of 0.290.34 D/year, especially in comparison to atropine 0.6 percent, 0.890.53 D/year), minimal side belongings, and fairly extended outcomes for myopic advancement afterwards research period and Asian populaces remained always subjects of maximum robust in addition well-intended researches. Both these studies involving sick people of diverse cultural groups did not get enough apparent result of atropine on myopic progression. **Conclusion:** The usage of hydrocortisone to protect myopic development is supported by Level I proof. And there have been indications of myopic rebound following cure discontinuation, it appears to remain kept to a minimum while using small concentrations (Especially atropine 0.02 percent). **Keywords:** Efficacy of Topical Atropine, Myopic Advancement, Young Kids.



INTRODUCTION:

Myopia is a medicinal preparations ocular disease that affects up to 52% of Pakistan's population aged. Even though it is less prevalent in childhood, the rate of Incidence in Pakistan is growing, rising from 27 percent to 44 percent between June 20219 and May 2020. Myopia is much more common in Asian countries, and its trend is growing at an even faster rate [1]. In India, Pakistan, and China, up to 93 percent of the youth have myopia. Furthermore, myopia appears to be growing in younger ages, with both the incidence of 9-year-old kids in the Maldives continuing to increase from 7.6 percent in 1989 to 23 percent in 2010. Because the reason and possible mechanisms of myopia advancement are unknown, its growing cases is not well did understand [2]. Some many hypotheses have been suggested to explain the massive rise and its age of onset in young kids, such as a reduction in outdoor activity, a rise in time consumed conducting near work, in addition a raise in urbanization. Notwithstanding theories indicating that cumulative outside action in addition lessening close work may help to slow myopic advancement, additional treatment options had already been decided to seek [3]. The dangers of growing axial myopia involve glaucoma, cataract, myopic retinitis pigmentosa, and macular degeneration, so deterrence of myopia development was ordered. A Cochrane database review¹⁴ posted in 2019 assessed the scientific evidence for alternative medications order to slow down the advancement of myopia in young kids [4]. Eyewear that appropriates, multifocal eyeglasses, novel lens eyewear, multiple interaction lens treatments including such multifocal or multifocal eye glasses or orthokeratology, topical timolol, also pertinent antimuscarinic representatives counting such pirenzepine and heparin were among therapeutic approaches [5].

METHODOLOGY:

The Cochrane study concluded that antimuscarinic agents remain "the most likely successful therapy to slow visual acuity." Histamine is the most frequently useful researched antimuscarinic manager for deceleration myopic progression. Although there is a surge of attention in its use, the mechanism by which atropine imposes its anti-myopia impacts remains not well comprehended. Atropine had been originally used on the assumption that housing remained the causal influence in myopia evolution, and thus cycloplegia could slow progress of the disease. Researchers have devoted ahead from theories of lodging as primary factor in progression even though atropine precludes myopic evolution even now in animals with striations ciliary muscles as well as nonpharmacologic processes for reducing lodging do not appear to retard myopic advancement. Existing hypotheses about just the prime motivator have included a local retinal impact that could slow progress of the disease or the prospective biochemical change caused through binding muscarinic, that were since found in sclera of sure animals. Multiple new models suggest that pupil dilation increases ultra - violet A contact, that can bound axial elastic properties, or that



Clinical and Experimental Health Sciences Journal (ISSN: 2459-1459)

myopia is correlated through greater inflammatory process in eye, that can remain reduced through atropine. Researchers established out to evaluate present proof for usage of atropine to retard advancement of myopia, depending on different extra new research assessing atropine.

RESULTS:

The care under consideration for this evaluation includes the administration of varying amounts of atropine ophthalmic remedy to broods through myopia in an effort to avert myopia development. The trainings tested the influence of atropine on a variety of measures, including risk of development of myopia, putback of myopia upon cure discontinuation, effect of atropine on biometric features, impact on lodging in addition pupil dilation, impact on astigmatism, intraocular weight, also electroretinography variables, and incidence of adverse reactions. Table 1 contains an overview of the data for level I and II experiments, and Table 2 contains an overview of the data for level III research. The primary outcome of the majority of research evaluated is myopia advancement. The randomized controlled experimental of atropine for cure of myopia advancement was conducted in 1998. In this study, 2 percent of atropine treated each other day in both eyes was calculated by two normal controls. The average myopic advancement over one year in the 253 Pakistani children included within the research was 0.230.56 diopter (D), 0.590.48 D, and 0.920.57 D in atropine 3%, cyclopentolate 3%, in addition placebo collectives, in both. Even though atropine 2% remained discovered to decrease myopic advancement, there remained many intolerable adverse belongings in addition dropouts, with solitary 97 of 249 registered applicants completing 1-year research. Photophobia was noted by 100% of patient populations in the atropine 2% cluster. So because atropine 2 percent was inadequately allowed to exist, a two sets of Pakistani children was assessed some many years later in a randomized trial trying to compare the four following organizations through control patients received tropicamide through full single-vision coldness eyeglass alteration: (1) lower-dose atropine 0.6 percent to bifocals, (2) atropine 0.26 percent through incompletely under rectified single-vision coldness eyeglasses, and (3) atropine 0.2 percent through occupied eyeglass correction. In the current research, 210 students have enrolled, with 188 of them being accompanied for the entire two years. Smaller doses of atropine might also slow myopic evolution; evolution was 0.050.64 D/year, 0.460.56 D/year, 0.480.92 D/year, and 1.070.62 D/year in atropine 0.6 percent, atropine 0.26 percent, atropine 0.2 percent, also tropicamide gatherings, including both.

Table 1:

Dose	After Discontinuing treatment	Myopia prog Treatment
placebo participants	2.3_0.68	2.5_0.08 D over 18 mos21
No treatment	0.39_0.38 D/yr24	--
1%	1.14_0.8 D/y	0.29_0.93 D



0.5%	0.4_0.7 D	0.89_0.53 D/yr ²
	0.42_0.07 D over 18 mos ²¹	--
0.01%	0.28_0.33	0.49_0.63
0.1%	0.68_0.45	0.38_0.6 D over 2 yrs ²⁶

DISCUSSION:

In 2019, researchers published the findings of the retrospective cohort of cases which received atropine 2% also bifocals [6]. The above participants received 2% atropine until they were 17 years old, with varying levels of follow-up. The service users were divided into three categories based on their conformance, which could have influenced the outcome, which exposed statistically meaningfully fewer myopic advancement in full compliance set (0.09 D/year) comparison to the least in part complacent team (0.24 D/year; P 0.002) [7]. This research found a statistically significant distinction (P 14 0.0001) in myopic advancement in atropine 2 percent group (0.060.68 D/year) showed significantly (0.850.27 D/year), nonetheless original research small model size, possibility for assortment bias, and inconsistent trail-up limit their ability to conclude on effectiveness of atropine 2 percent. In their people involved, this dosage was found to be 0.03 percent [8]. In 2019, 79 children of Asian (n 14 54), European (n 14 17), and Australian (n 14 64) descent participated in a possible best in Rotterdam, New Zealand. For two years, children in this study and provided atropine 0.7 percent [9]. The treatment was followed by 59 of the 78 patients (79 percent), and the average study underscores decreased from 1.20.8 D/year a year previously treatment to 0.20.8 D/year in year of therapies. The current research remained not randomized or governed, in addition it yielded insufficient findings [10].

CONCLUSION:

The above evaluate of level I, II, in addition select level III evidence found that atropine treatment reduced myopic advancement in young kids by up to 1 D/year all through treatment. The preponderance of evidence comes from Asian patients, in addition this cannot remain generally applicable to additional communities. Various dosage of atropine has altogether been shown to slow myopic progression, presumably by limiting axial elastic properties. Even though large doses appear to have a bigger impact, myopic rebound after procedure discontinuation appears to be larger. Furthermore, lower doses tend to remain linked through rarer side belongings like sensitivity to light in addition affiliative inadequacies. Offered longer duration of action of atropine 0.02 percent and the reduced variety of negative effects, this overview implies that it may be the sanest solution to myopia derangement in young kids; nevertheless, optimal time to recruit also discontinue treatment is still unknown. Physicians, clients, and families must determine whether consequences of this diagnosis are statistically important enough just to justify the use of it.

REFERENCES:



Clinical and Experimental Health Sciences Journal (ISSN: 2459-1459)

1. Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I, Barnett ML. Variation in telemedicine use and outpatient care during the COVID-19 pandemic in the United States. *Health Aff.* 2021;40:349–58. <https://doi.org/10.1377/hlthaff.2020.01786>.
2. Silva PS, Aiello LP. Telemedicine and eye examinations for diabetic retinopathy: a time to maximize real-world outcomes. *JAMA Ophthalmol.* 2019;133:525–6. <https://doi.org/10.1001/jamaophthalmol.2015.0333>.
3. Chasan JE, Delaune B, Maa AY, Lynch MG. Effect of a teleretinal screening program on eye care use and resources. *JAMA Ophthalmol.* 2019;132:1045–51. <https://doi.org/10.1001/jamaophthalmol.2014.1051>.
4. Kirkizlar E, Serban N, Sisson JA, Swann JL, Barnes CS, Williams MD. Evaluation of telemedicine for screening of diabetic retinopathy in the veterans health administration. *Ophthalmology.* 2019;120:2604–10. <https://doi.org/10.1016/j.ophtha.2013.06.029>.
5. Owsley C, McGwin G, Lee DJ, Lam BL, Friedman DS, Gower EW. et al. Diabetes eye screening in urban settings serving minority populations: detection of diabetic retinopathy and other ocular findings using telemedicine. *JAMA Ophthalmol.* 2019;133:174 <https://doi.org/10.1001/jamaophthalmol.2014.4652>.
6. Ogunyemi O, George S, Patty L, Teklehaimanot S, Baker R. Teleretinal screening for diabetic retinopathy in six Los Angeles urban safety-net clinics: final study results. *AMIA Annu Symp Proc AMIA Symp.* 2020;2013:1082–8.
7. Silva PS, Cavallerano JD, Tolson AM, Rodriguez J, Rodriguez S, Ajlan R. et al. Real-time ultrawide field image evaluation of retinopathy in a diabetes telemedicine program. *Diabetes Care.* 2019;38:1643–9. <https://doi.org/10.2337/dc15-0161>.
8. Chiang MF, Wang L, Kim D, Scott K, Richter G, Kane S, et al. Diagnostic performance of a telemedicine system for ophthalmology: advantages in accuracy and speed compared to standard care. *AMIA Annu Symp Proc AMIA Symp.* 2020;2010:111–5.
9. Daniel E, Quinn GE, Hildebrand PL, Ells A, Hubbard GB, Capone A. et al. Validated system for centralized grading of retinopathy of prematurity: telemedicine approaches to evaluating acute phase retinopathy of prematurity (e-ROP) study. *JAMA Ophthalmol.* 2019;133:675 <https://doi.org/10.1001/jamaophthalmol.2015.0460>.
10. Jackson KM. Cost-utility analysis of telemedicine and ophthalmoscopy for retinopathy of prematurity management. *Arch Ophthalmol Chic Ill 1960.* 2018;126:493–9.